Fate Therapeutics Reports Financial Results and Strategic Updates in 10-K Filing
Fate Therapeutics Inc. has released its 10-K filing, detailing the company's financial performance and strategic developments. The company, focused on off-the-shelf cellular immunotherapies, reported collaboration revenue of $6.6 million for the year ended December 31, 2025, a decrease from $13.6 million in the previous year. This decline was primarily attributed to the achievement of a clinical development milestone in 2024, which resulted in a one-time revenue recognition of $5.0 million. Research and development expenses decreased to $107.8 million from $135.0 million, while general and administrative expenses also saw a reduction, falling to $46.5 million from $74.2 million. The company reported a net loss of $136.3 million for 2025, compared to a net loss of $186.3 million in 2024.
The company's strategic focus remains on its iPSC product platform, developing off-the-shelf CAR-targeted T-cell and NK cell product candidates. A key development was the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation granted to FT819 for treating moderate-to-severe Systemic Lupus Erythematosus (SLE). Fate Therapeutics also received authorization to initiate clinical trials of FT819 in the U.K. and EU. The company is expanding its clinical investigations into additional B cell-mediated autoimmune diseases, including anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc).
Operationally, Fate Therapeutics continues to advance its CAR T-cell immunotherapies for solid tumors, with FT825 currently undergoing Phase 1 clinical investigation in collaboration with Ono Pharmaceutical. The company also initiated Phase 1 clinical investigation of FT836 for the treatment of solid tumors. The first patient with stage IV colorectal cancer was treated with FT836 in November 2025. The company is also completing IND-enabling activities in 2026 to support the initial clinical investigation of FT839 for the treatment of cancer and autoimmune diseases. As of December 31, 2025, the company employed 161 full-time employees, with a significant portion dedicated to clinical development, manufacturing, and regulatory affairs.
Looking ahead, Fate Therapeutics plans to continue its regulatory development of FT819 in SLE, with the submission of a Phase 2 registration-enabling clinical protocol in lupus nephritis. The company also intends to investigate the potential of FT819 as a treatment for extrarenal lupus in a second trial, with the ultimate goal to advance to biologics license application (BLA) filing over the course of the next several years. The company will continue to seek partnerships with companies and institutions for the research, development and commercialization of iPSC-derived cell therapies for the treatment of human diseases. As of December 31, 2025, Fate Therapeutics had $205.1 million in cash, cash equivalents, and investments.
About FATE THERAPEUTICS INC
Fate Therapeutics is a biopharmaceutical company developing off-the-shelf cellular immunotherapies using proprietary induced pluripotent stem cell (iPSC) technology. Its focus includes engineered T-cell and natural killer (NK) cell products for autoimmune diseases and solid tumors. The company leverages innovative synthetic controls, gene editing, and scalable manufacturing to create targeted, durable, and accessible cell therapies aimed at addressing unmet medical needs across cancer and autoimmune indications.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.